Groundbreaking New FDA-Approved Drug for Acute Leukemia
A landmark in cancer treatment has come full circle, as the U.S. Food and Drug Administration (FDA) approved revumenib, a revolutionary drug for relapsed or refractory acute leukemia with a KMT2A translocation on November 15, 2024. This life-saving therapy, first administered to a Florida Cancer Specialists & Research Institute, LLC (FCS) patient at its Sarasota Drug Development Unit (DDU) in 2019 as part of a Phase 1 clinical trial, is now available to patients nationwide. The very first patient to ever receive this groundbreaking treatment was referred by FCS medical oncologist/hematologist Muhammad Imam, MD to FCS Director of Drug Development Manish R. Patel, MD at the FCS Sarasota DDU, one of three early-phase clinical trial sites within the statewide practice. This milestone underscores FCS‘ fundamental role in the development of this drug, which has now gained FDA approval for its…





